OR WAIT null SECS
October 02, 2017
The agency published four guidance documents regarding ANDAs and amendments to ANDAs.
Industry and FDA face new fee structures and new challenges in implementing fee initiatives.
Focusing on whether the product meets its defined quality attributes should help one make reasonable, documentable, and defendable risk-based decisions, according to Susan Schniepp, distinguished fellow at Regulatory Compliance Associates.
September 28, 2017
The draft guidance gives recommendations for reproductive toxicity testing and labeling.
FDA sent a warning letter to Shandong Vianor Biotech Co., Ltd. that claimed the company failed to follow proper data integrity and quality control procedures.
The agency will require training for healthcare providers who prescribe immediate-release opioids.
September 27, 2017
The FDA commissioner made a statement about the agency’s efforts to ensure patient access to safe compounded medicines.
September 25, 2017
Pharmaceutical companies should prepare for the impact of recalls to minimize risk to consumers and the company.
September 21, 2017
The agency sent out 13 warning letters on Sept. 19, 2017 to companies selling drug products online.
September 19, 2017
Validation and batch testing failures were among the violations found by the FDA at the company’s Jiangsu facility.